VELCADE,Rituximab,Cyclophosphamide and Decadron

This is a phase II open label study that is looking at the VRCD combination regimen in
patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start by
combining oral dexamethasone and cyclophosphamide with intravenous VELCADE, rituximab.
Chemotherapy cycles will be given as outlined below every 35-days and will continue until two
cycles beyond complete remission (CR), toxicity, patient's withdrawal, disease progression,
or a maximum of 8 cycles.

Inclusion Criteria:

- Small Lymphocytic Lymphoma

- Follicular Cell Lymphoma (grades I and II)

- Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy
and stem cell transplant

- Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia

- Marginal Zone Lymphoma

- MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.

- Adequate bone marrow function, renal function, and hepatic function as outlined in
details below.

- ECOG performance status of 0, 1, or 2

- Able to read, understand, and sign an IRB approved informed consent

Exclusion Criteria:

- Known HIV positive status

- Known CNS involvement

- Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.